circular RNAs

CAR-T therapy
#CAR-T #Cell therapy #Circio Holding #circular RNAs #Financing

Circio raises NOK 200 million towards in vivo CAR-T programme

Circio Holding has successfully completed a private placement raising gross proceeds to the company of approx. NOK 200 ($21) million, through the allocation of 16,865,000 new shares.  The Offer Price corresponds to a 9% discount to the volume weighted average share price (VWAP) quoted for trade in the company's shares… Read More

#Business & Investment #News

#Cell and gene therapy #Circio Holding #circular RNAs #Collaboration #NeoRegen Biotech #RNA

NeoRegen and Circio progress circular RNA research collaboration

Circio Holding and NeoRegen Biotech have signed a second Material Transfer Agreement (MTA) to advance their ongoing collaboration for the delivery of circular RNA (circRNA) expression-based therapeutics.   The collaboration now is progressing to the in vivo preclinical stage following successful proof-of-concept (POC) results from in vitro studies.  The collaboration… Read More

#Business & Investment #News

Circular DNA concept
#Cell and gene therapy #Circio Holding #circular RNAs #In vitro #In vivo

Circular RNA technology could open new therapeutic opportunities

Circular RNA technology continues to demonstrate broad capability to significantly boost protein expression level and durability for both viral and non-viral gene and cell therapy, according to new data.  Circio Holding shared the new and strengthened in vivo data for its circVec platform at the… Read More

#News

#circular RNAs #Phase I trial #RiboX Therapeutics #RNA

First circular RNA begins trials in radiation-induced xerostomia

RiboX Therapeutics has dosed the first patient in its first-in-human (FIH) Phase I/IIa clinical trial (SPRINX-1) evaluating the safety and efficacy of RXRG001 in patients with radiation-induced-xerostomia (RIX) and hyposalivation.  RXRG001 is the first circular RNA therapy to receive FDA IND clearance.  Xerostomia and hyposalivation… Read More

#News #Trending News

mRNA
#Circio Holding #circular RNAs #DNA #Funding #mRNA #Norway #RNA #Viral vectors

NOK 10.7 million supports circular mRNA technology

Biotechnology company Circio Holding has secured approximately NOK 10.7 million (€907.4k) in financing to support the development of its circVec circular mRNA technology. The major allocations in the financing were to existing shareholders Høse AS and Bækkelaget Holding AS, and new shareholders Star Kapital AS (v/ Tom A Thorsen) and… Read More

#News

Simon and Vanessa Conn
#Cancer treatment #circular RNAs #Flinders University #Oncology #Personalised medicine #RNA

Harnessing circRNAs could “change the landscape” of cancer therapy

Circular RNAs (circRNAs) have “remarkable potential” to improve cancer treatment and patient outcomes within the next five to 10 years, according to a new study by Flinders University in Australia. The research was led by Senior Researcher Dr Vanessa Conn and Professor Simon Conn, who leads… Read More

#Cancer Research #Editor's Choice #News

RNA
#Circio Holding #circular RNAs #Gene therapy #Genetic diseases #In vivo #mRNA

How does circVec technology compare to conventional mRNA? 

Circio has announced updated in vivo data that demonstrates a substantial durability advantage of Circio’s circVec technology over conventional mRNA expression. In addition, Circio has undertaken sequence optimisation resulting in a new circVec 2.2 design.   “The circVec 2.1 design is performing very well in… Read More

#News

#Cardiovascular disease #Cell and gene therapy #Cell therapy #circular RNAs #Gene therapy

New DDW Highlights podcast: 21 May 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  From a weight loss drug that prevents heart attacks and a gene therapy that… Read More

#News

#Cardiovascular disease #Cell and gene therapy #Cell therapy #circular RNAs #Gene therapy

This week in drug discovery (13-16 May) 

News round-up for 13-16 May by DDW Senior Digital Content Editor Diana Spencer. From a weight loss drug that prevents heart attacks and a gene therapy that restores hearing, to a vaccine that can treat viruses that don’t exist yet, our chosen news stories this week all represent… Read More

#News

RNA strand
#Circio Holding #circular RNAs #Gene therapy #Genetic diseases #In vivo #mRNA

Data demonstrates superiority of circular RNA vs linear mRNA

In vivo proof-of-concept for Circio Holding’s differentiated circVec platform approach to gene therapy has been demonstrated in two posters at the American Society of Gene & Cell Therapy (ASGCT) 2024 annual meeting. The in vivo data showed statistically significant higher expression level and durability for circVec… Read More

#News

Genetic engineering RNA
#Antisense Oligonucleotides (ASOs) #circular RNAs #Immunology / Virology & Vaccines #mRNA #RNA sequencing #siRNA

World RNA Day: What impact has RNA had on drug discovery?  

1 August was first chosen as World RNA Day in 2018 as a play on AUG (adenine, uracil and guanine), a triple sequence of RNA (called a codon) that initiates protein synthesis by the cell. Since then, it has been observed to publicise the importance of this molecule in the… Read More

#Exclusive Content

Colorectal Cancer Awareness Month
#Cancer research #circular RNAs #Colorectal cancer #Immuno-oncology #Immunotherapy #Oncology

Colorectal Cancer Awareness Month: Drug discovery innovation

Diana Spencer explores the different ways the drug discovery sector is tackling colorectal cancer. Colorectal cancer is preventable with screening and often treatable when caught early, yet due to late diagnosis and chemotherapy resistance, it remains the second deadliest cancer in the United States. Held in the US March every… Read More

#Cancer Research #Exclusive Content

Research lab
#Cancer research #circular RNAs #Collaboration #Esperovax #Ginkgo Bioworks #High throughput screening #Oncology #Partnership #RNA

Alliance to develop circular RNA-based therapeutics

Esperovax and Ginkgo Bioworks have agreed a partnership to develop circular RNAs (circRNAs) for a variety of therapeutic applications.   Initially, the companies will work to develop circRNAs harbouring payloads to specifically target colorectal cancer by inducing cell death only in cancerous cells.  CircRNAs represent an… Read More

#Cancer Research #News